OTC · Drug Manufacturers - Specialty & Generic

Bachem Holding AG (BCHMF) Stock

$91.00 +0.00% OTC: BCHMF Healthcare

Bachem Holding AG is a global partner to pharmaceutical and biotechnology companies, supplying crucial products and services for every stage from early-stage research and clinical trials to full-scale commercialization. The company specializes in the creation, manufacturing, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide chemical entities (NCEs).

Valuation

MetricValue
Price$91.00
Market Cap$6.82B
P/E Ratio37.01
P/B Ratio3.82
P/S Ratio7.79
EPS (TTM)$2.46
52-Week High$94.62
52-Week Low$60.51
Dividend Yield0.64%

Financials & Margins

MetricValue
ROE10.27%
ROA6.37%
ROCE7.54%
Gross Margin27.00%
Operating Margin19.41%
Net Margin21.02%
Debt/Equity0.14
Current Ratio1.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$503.0M$532.0M$577.0M$605.0M$695.0M
Operating Profit$129.0M$127.0M$129.0M$133.0M$150.0M
Net Profit$115.0M$101.0M$112.0M$120.0M$149.0M
EPS$1.62$1.37$1.50$1.60$1.98
Op Margin25.6%23.9%22.4%22.0%21.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.4B$1.7B$1.9B$2.1B
Total Liabilities$177.0M$214.0M$362.0M$532.0M$651.0M
Cash$89.0M$31.0M$158.0M$95.0M$31.0M
Borrowings$21.0M$1.0M$0$0$57.0M

Latest News

Bachem Holding AG (BCHMF) (H1 2026) Earnings Call Highlights: Strategic Expansion and Refined ... GuruFocus.com · Aug 1, 2026 Bachem Confirms Growth and Expects a Strong Second Half 2026 TMX Newsfile · Jul 30, 2026 Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld TMX Newsfile · Jul 21, 2026 Bachem Holding (SWX:BANB) Stock Valuation Check After Recent Share Price Pullback Simply Wall St. · Jun 15, 2026 Bachem Holding AG Announces Capital Markets Day 2026 TMX Newsfile · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$98.0M$93.0M$250.0M$146.0M$271.0M
Investing Cash Flow$-586.0M$-205.0M$-439.0M$-433.0M$-645.0M
Financing Cash Flow$-1.0M$-2.0M$-1.0M$-1.0M$-3.0M
Net Cash Flow$66.0M$-58.0M$126.0M$-63.0M$-52.0M
Free Cash Flow$-19.0M$-50.0M$-19.0M$-138.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio3.31
EV / EBITDA29.94
FCF Yield-0.86%
Quick Ratio0.49
Interest Coverage110.97
Return 1Y49.64%
Return 3Y10.73%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARKAFArkema S.A. $68.44 +0.00% 107.81 $5.18B 5.86%
COIHFCroda International Plc $40.61 +0.00% 58.15 $5.66B 4.19%
COIHYCroda International Plc $22.17 +0.82% 57.73 $6.19B 2.89%
FUPEFFuchs Petrolub SE $37.00 +0.00% 15.72 $4.85B 3.89%
FUPPFFuchs Petrolub SE $46.85 +0.00% 15.72 $5.24B 3.09%

About Bachem Holding AG

Bachem Holding AG is a global partner to pharmaceutical and biotechnology companies, supplying crucial products and services for every stage from early-stage research and clinical trials to full-scale commercialization. The company specializes in the creation, manufacturing, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide chemical entities (NCEs). Beyond these, Bachem also offers established commercial NCEs and generic medications. Its comprehensive service offerings include project oversight, quality assurance, regulatory compliance guidance, advanced analytical testing, GMP-compliant production, specialized research-grade manufacturing, and integrated supply chain solutions. The company, established in 1971, operates from its headquarters in Bubendorf, Switzerland.

Bachem Holding AG is headquartered in CH.

Bachem Holding AG (BCHMF) stock trades at $91.00 with a market capitalization of $6.82B. The stock is valued at a price-to-earnings (P/E) ratio of 37.01, price-to-book of 3.82, price-to-sales of 7.79. Over the past 52 weeks the stock has ranged between $60.51 and $94.62, and currently trades 3.8% below its 52-week high. It pays a dividend yielding 0.64%.

On profitability, Bachem Holding AG generates a return on equity (ROE) of 10.27%, return on capital employed of 7.54%, an operating margin of 19.41%, a net profit margin of 21.02%.

Official website: www.bachem.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides